Search Results

Imugene, Ltd. and Kincell Bio, LLC, announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice manufacturing facility and the transfer of process and analytical development activities to Kincell.

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that enrolment has opened for its expansion study in bile tract cancer (cholangiocarcinoma) patients, having completed the fifth, high dose cohort in the intratumoural (IT) arm of the monotherapy dose escalation study evaluating its cancer-killing virus CF33-hNIS (VAXINIA).

Imugene Limited, a clinical stage immuno-oncology company, highlighted recent progress across the company’s immuno-oncology portfolio and provided an update on anticipated upcoming milestones.

MaxCyte, Inc. and Imugene announced the signing of a strategic platform license.

Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) currently being conducted in San Francisco.

Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.

Imugene Ltd and NeoImmuneTech, Inc. announced a strategic collaboration to evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T cell amplifier “Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.